Omgenis Signs Exclusive Worldwide Licence Agreement with the University of Pittsburgh

Omgenis has signed an exclusive worldwide licence agreement with the University of Pittsburgh covering proprietary magnesium microparticle technology for applications in periodontal and peri-implant tissue regeneration.

The agreement grants Omgenis exclusive global rights to develop and commercialise the licensed technology in the fields of periodontitis and peri-implantitis. It establishes a strong foundation for the company’s product-development programme and international commercial strategy.

Omgenis is developing the technology as a locally administered, biodegradable medical device intended to complement established periodontal procedures. The magnesium-based microparticles are designed to provide a temporary degradable matrix within the treated tissue, supporting local tissue healing and regeneration and the associated recovery of alveolar bone. The technology is based on biodegradable magnesium microparticles whose controlled degradation is an inherent part of the material’s performance. The resulting biological responses are intended to stop disease from progressing and to support the regenerative process while the material is progressively resorbed. The collaboration brings together scientific innovation originating from the University of Pittsburgh and Omgenis’s focus on translating advanced biomaterials research into clinically meaningful and commercially viable medical-device solutions for oral healthcare.

‍